None listed
Conditions
Interventions
Intervention1: Immersive Virtual Reality (IVR) Group: Virtual reality device is a spectacle like device strapped in front of eyes which shows 360° view of 3- dimensional scenario like a kaleidoscope.
Sponsors
WUNDRSIGHT PRIVATE LIMITED
Carmel Research Consultancy Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1.All consenting CDSIMER(Dr.Chandramma Dayananda Sagar Institute of Medical Education and Research) and DSU(Dayananda Sagar University) teaching and non-teaching staff between the ages of 18 and 60. 2.Willing and able to give informed consent.
Exclusion criteria
Exclusion criteria: 1.Participants with known or diagnosed psychiatric disorders and already on any form of treatment 2.Participants with Perceived Stress Scale (PSS) Score less than 13. 3.Participants with known comorbid medical conditions, such as endocrine (e.g., thyroid and adrenal), cardiovascular, neurological disorders, autonomic neuropathy, acute or chronic painful conditions, and any other significant inflammation, infection, or fever on the day of the procedure. 4.Current or prior diagnosis of epilepsy, seizure disorder, dementia, migraines or other neurological disease that may prevent the use of VR. 5.Participants taking any medication that may affect physiological parameters under study, such as antihypertensives, beta- and alpha-receptor modulators, psychotropic medications, anticholinergics, cholinergic, or any unknown formulation. 6.Pregnant and lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Mean difference in self-reported Relaxation State Questionnaire(RSQ) Score from baseline to end of the intervention.Timepoint: At time 0 and time 0 plus 20 minutes | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Change in average Heart Rate in 5-minute tracing from baseline to end of the intervention. 2.Change in average Respiratory Rate in 5-minute tracing from baseline to end of the intervention. 3.Change in average Blood Pressure in 5-minute tracing from baseline to end of the intervention. 4.Change in Heart Rate Variability(HRV) index from baseline to end of the intervention. 5.Account of any adverse events(Nausea, Lightheadedness, eye strain, any other event leading to discontinuation of the session) Timepoint: At time 0 and time 0 plus 20 minutes | — |
Countries
India
Contacts
Public ContactProf Dr Alben Sigamani
CDSIMER-Dr. Chandramma Dayananda Sagar Institute of Medical Education & Research
Outcome results
None listed